Literature DB >> 18714629

The use of extracorporeal carbon dioxide removal in the management of life-threatening bronchospasm due to influenza infection.

S Twigg1, G J Gibbon, T Perris.   

Abstract

We report the use of the Novalung interventional Lung Assist extracorporeal carbon dioxide removal device, (Novalung GmbH, Lotzenacker 3, D-72379 Hechingen, Germany) to treat a 46-year-old female with life-threatening bronchospasm secondary to influenza infection. Despite maximal treatment she developed severe hypercapnia and acidosis. The necessity for high inflation pressures led to the development of gross surgical emphysema. Use of the interventional Lung Assist enabled a rapid correction of hypercapnoea and acidosis, allowing a reduction in airway pressures, reducing further barotrauma. Subsequent resolution of the inflammatory process allowed removal of the interventional Lung Assist after 11 days. She was successfully weaned from mechanical ventilation and made a full recovery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18714629     DOI: 10.1177/0310057X0803600424

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  3 in total

1.  Extracorporeal life support for management of refractory cardiac or respiratory failure: initial experience in a tertiary centre.

Authors:  Adriano Peris; Giovanni Cianchi; Simona Biondi; Manuela Bonizzoli; Andrea Pasquini; Massimo Bonacchi; Marco Ciapetti; Giovanni Zagli; Simona Bacci; Chiara Lazzeri; Pasquale Bernardo; Erminia Mascitelli; Guido Sani; Gian Franco Gensini
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2010-05-21       Impact factor: 2.953

2.  A Double Catheter Approach for Extracorporeal CO2 Removal Integrated Within a Continuous Renal Replacement Circuit.

Authors:  David De Bels; Charalampos Pierrakos; Herbert D Spapen; Patrick M Honore
Journal:  J Transl Int Med       Date:  2018-12-31

3.  Extracorporeal life support for acute respiratory distress syndromes.

Authors:  Don Hayes; Joseph D Tobias; Jasleen Kukreja; Thomas J Preston; Andrew R Yates; Stephen Kirkby; Bryan A Whitson
Journal:  Ann Thorac Med       Date:  2013-07       Impact factor: 2.219

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.